Update on osteoporosis treatment

Xavier Nogués, Daniel Martinez-Laguna

Research output: Contribution to journalReview articleResearchpeer-review

12 Citations (Scopus)


© 2017 Elsevier España, S.L.U. Treatment of osteoporosis should be directed primarily towards secondary prevention of fractures. The occurrence of drug-related adverse effects for the treatment of osteoporosis has led to a reevaluation of the indications, the duration of treatment and even withdrawal of some drugs from the market. This review has been made from different patient profiles that practitioners will find in usual practice; from patients with hip fracture with cognitive impairment, limitation of their day-to-day living activities and comorbidities, to active patients without any limitations; patients with vertebral fractures and non-vertebral fractures where secondary prevention is highly important. In general, antiresorptive drugs (alendronate and risedronate) will be the first choice. Zoledronate or denosumab will be indicated in cases of digestive intolerance, poor adherence or an increased risk of hip fracture. Teriparatide will be indicated to patients with 2 or more previous vertebral fractures or very low bone density.
Original languageEnglish
Pages (from-to)479-486
JournalMedicina Clinica
Issue number12
Publication statusPublished - 22 Jun 2018


  • Fragility fractures
  • Osteoporosis
  • Secondary prevention
  • Treatment


Dive into the research topics of 'Update on osteoporosis treatment'. Together they form a unique fingerprint.

Cite this